Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01798589 · ClinicalTrials.gov registry record · Phase 4
Bioequivalence of Ethylenediamine Dihydrochloride Study
A Phase 4 study, sponsored by Allerderm.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT01798589 is a Phase 4 study that has completed, run by Allerderm. The registered enrollment target is 16 participants.
The verdict
NCT01798589, a Phase 4 study, has completed, sponsored by Allerderm.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the allergen ethylenediamine dihydrochloride when prepared using methylcellulose versus preparation using polyvinylpyrrolidone.
Interventions
- DRUG Ethylenediamine dihydrochloride allergen patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01798589
The ClinicalTrials.gov registry entry for NCT01798589 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allerderm, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ethylenediamine dihydrochloride allergen patch is the first listed.
NCT01798589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01798589 about?
NCT01798589 is a clinical study titled "Bioequivalence of Ethylenediamine Dihydrochloride Study". The purpose of this study is to compare the allergen ethylenediamine dihydrochloride when prepared using methylcellulose versus preparation using polyvinylpyrrolidone.
What is the current status of trial NCT01798589?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2012-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01798589?
The interventions under investigation include: Ethylenediamine dihydrochloride allergen patch (DRUG).
Who is sponsoring clinical trial NCT01798589?
This trial is sponsored by Allerderm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.